Hypoparathyroidism Program
Hypoparathyroidism
DiscoveryActive
Key Facts
About Confo Therapeutics
Confo Therapeutics is a Belgian clinical-stage biotech pioneering a unique approach to drug discovery for GPCRs, a historically challenging but highly druggable target class. The company's proprietary platform enables the development of both small molecules and antibodies, with a pipeline focused on metabolic and endocrine conditions, including neuropathic pain, obesity, and post-bariatric hypoglycemia. Backed by a €60M Series B financing and strategic partnerships, Confo is advancing its lead candidate, CFTX-1554, into Phase 1 while expanding its early-stage pipeline. The company operates as a private, pre-revenue entity leveraging its technology for internal programs and potential collaborations.
View full company profileTherapeutic Areas
Other Hypoparathyroidism Drugs
| Drug | Company | Phase |
|---|---|---|
| Palopegteriparatide (TransCon PTH) | VISEN Pharmaceuticals | Phase 3 |
| Oral Long-Acting PTH Tablet | Opko Health | Preclinical |
| EB-612 | Extend Biosciences | Phase 2 |
| Canvuparatide (MBX 2109) | MBX Biosciences | Phase 2 |
| SEP-479 (PTH1R) | Septerna | Phase 2 |
| EB612 (oral PTH(1-34)) | Entera Bio | Phase 2 |
| Oral Long-Acting PTH | Entera Bio | Discovery/Preclinical |